News

Lack of sleep on a regular basis or waking up several times during the night may be harmful to the brain and increase the risk of developing Alzheimer’s disease, according to recent evidence. Patients with Alzheimer’s disease tend to sleep poorly and stay awake more often at night. However, researchers have…

PsychoGenics Inc. and the Alzheimer’s Drug Discovery Foundation (ADDF) announced a collaboration that opens PsychoGenics’ Alzheimer’s animal models and investigational services to recipients of ADDF grants who are working in preclinical Alzheimer’s drug discovery programs. Through the collabortion, PsychoGenics will offer its products and services to ADDF-funded biotechnology companies on “extremely favorable…

Neuralstem Inc. researchers have released the preclinical results of a human stem cell line with the potential to treat Alzheimer’s disease patients. The research paper, “Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-I: A Novel Cellular Therapy for Alzheimer’s Disease,” was published in the journal Stem Cells Translational Medicine. Neuralstem’s…

Evotec AG has reached an important milestone concerning its TargetAD partnership with Janssen Pharmaceuticals for the transition of a product into further drug discovery process. Even though the announcement was made this year, the milestone was reached in 2015. Evotec’s TargetAD database is a customized system to provide unique information on the connection between molecular…

Austin-based Alzheimer’s Association Capital of Texas Chapter (known as Alzheimer’s Texas) announced that the organization has separated from the national organization, based in Chicago. The organization, a leader in Alzheimer’s care, education, and support in Central Texas, and the state’s pre-eminent force for new funding for Alzheimer’s disease and dementia research, says that the…

Anavex Life Sciences Corp. reported that a positive dose-response relationship has been observed in its ongoing Phase 2a clinical trial of ANAVEX 2-73 as a potential treatment for mild-to-moderate Alzheimer’s disease (AD). The announcement came as part of a planned, interim study analysis. The ANAVEX 2-73 Phase 2a study is a multicenter trial…

University of Texas at Arlington (UTA) researchers will study the catalytic processes of sulfur-oxidizing enzymes, especially the chemical mechanism of a key enzyme, cysteine dioxygenase. Their work could lead to new therapies for Alzheimer’s and autism, diseases in which sulfur metabolism is known to be disrupted. Dr. Brad Pierce, a UTA assistant professor of biochemistry,…

Researchers at the Scintillon Institute for Biomedical and Bioenergy Research, San Diego, have discovered that the high blood sugar levels that mark type 2 diabetes and the plaque-forming β-amyloid protein found in Alzheimer’s disease (AD) cause the same alterations in several brain enzymes. The findings explain the association long observed between AD and diabetes. The results,…

British researchers recently identified a protein driving brain inflammation, CSF1R, which they think may be the driving force behind the progression of Alzheimer’s disease (AD). The study, “Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology” and published in the journal Brain, could be a significant step forward in…

Tetra Discovery Partners, in collaboration with the NIH Blueprint Neurotherapeutics Network, announced the start of Phase 1 safety trials of BPN14770, a drug Tetra is developing as a potential treatment for neurological disorders such as Alzheimer’s disease (AD) and one that aims to both improve memory and slow disease progression. The NIH Blueprint Neurotherapeutics…